chloroadenosine

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: chloroadenosine
• 英文别名: (2S,3R,4S,5R)-2-(6-aminopurin-9-yl)-2-chloro-5-(hydroxymethyl)oxolane-3,4-diol
• 化学式: C₁₀H₁₂ClN₅O₄
• 分子量: 301.689
• InChiKey: PLDLXZBHSVQZNN-CRKDRTNXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  140
• 氢给体数：
  4
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  腺苷 、 、 氯化亚砜 、 吡啶 在 ice 、 水 、 乙腈 、 甲醇 、 ammonium hydroxide 作用下， 以 乙腈 为溶剂， 反应 58.75h， 以The reaction afforded chloroadenosine as a colorless crystalline solid (98.9 g, 92.7%)的产率得到chloroadenosine
  参考文献：
  名称：

  Combination therapies for treating methylthioadenosine phosphorylase deficient cells

  摘要：

  本发明涉及用于治疗哺乳动物中与甲基硫腺苷磷酸化酶（MTAP）缺乏细胞相关的细胞增殖性疾病的联合疗法。该联合疗法通过给予新生核苷酸合成抑制剂和给予抗毒性剂，选择性地杀死MTAP缺乏细胞，其中，新生核苷酸合成抑制剂是甘氨酰核苷酸甲酰转移酶（“GARFT”）和/或氨基咪唑羧酰核苷酸甲酰转移酶（“AICARFT”）的抑制剂，抗毒性剂是MTAP底物（例如，甲基硫腺苷或“MTA”），MTA的前体，MTA前体的类似物或MTAP底物的前药。

  公开号：

  US20040043959A1

文献信息

• [EN] HPPK INHIBITORS USEFUL AS ANTIBACTERIAL AGENTS<br/>[FR] INHIBITEURS DE HPPK UTILES EN TANT QU'AGENTS ANTIBACTÉRIENS
  申请人：US HEALTH

  公开号：WO2018071531A1

  公开（公告）日：2018-04-19

  The disclosure provides linked purine pterin compounds of Formula I that are novel inhibitors of HPPK, a kinase responsible for an essential step in the biosynthesis of folic acid. (Formula I) The variables, e.g., A1-A3, R1-R4, B1-B2, and L1 are defined in the disclosure. These linked purine pterin inhibitors bind to HPPK with high affinity and specificity. Pharmaceutical compositions containing the HPPK inhibitors and methods of treating a bacterial infection in a patient with one or more of the HPPK inhibitors of the disclosure are also provided.

  该披露提供了一种 Formula I 的嘌呤-喹啉化合物，这些化合物是 HPPK 的新型抑制剂，HPPK 是叶酸生物合成中一个关键步骤的激酶。变量，例如 A1-A3、R1-R4、B1-B2 和 L1 在该披露中有定义。这些嘌呤-喹啉抑制剂与 HPPK 结合具有高亲和力和特异性。还提供了含有 HPPK 抑制剂的药物组合物以及使用该披露中的一个或多个 HPPK 抑制剂治疗患者细菌感染的方法。
• MODULAR RADIOCHEMISTRY SYNTHESIS SYSTEM
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：US20150329583A1

  公开（公告）日：2015-11-19

  A modular chemical production system includes multiple modules for performing a chemical reaction, particularly of radiochemical compounds, from a remote location. One embodiment comprises a reaction vessel including a moveable heat source with the position thereof relative to the reaction vessel being controllable from a remote position. Alternatively the heat source may be fixed in location and the reaction vial is moveable into and out of the heat source. The reaction vessel has one or more sealing plugs, the positioning of which in relationship to the reaction vessel is controllable from a remote position. Also the one or more reaction vessel sealing plugs can include one or more conduits there through for delivery of reactants, gases at atmospheric or an elevated pressure, inert gases, drawing a vacuum and removal of reaction end products to and from the reaction vial, the reaction vial with sealing plug in position being operable at elevated pressures. The modular chemical production system is assembled from modules which can each include operating condition sensors and controllers configured for monitoring and controlling the individual modules and the assembled system from a remote position. Other modules include, but are not limited to a Reagent Storage and Delivery Module, a Cartridge Purification Module, a Microwave Reaction Module, an External QC/Analysis/Purification Interface Module, an Aliquotting Module, an F-18 Drying Module, a Concentration Module, a Radiation Counting Module, and a Capillary Reactor Module.

  一个模块化的化学生产系统包括多个模块，用于从远程位置执行化学反应，特别是放射化学化合物的反应。一个实施例包括一个反应容器，其中包括一个可移动的热源，其相对于反应容器的位置可以从远程位置控制。另一种情况是热源可能固定在某个位置，而反应瓶可以移动进入和移出热源。反应容器有一个或多个密封塞，其相对于反应容器的位置可以从远程位置控制。此外，一个或多个反应容器密封塞可以包括一个或多个通道，用于提供反应物、大气或高压气体、惰性气体、抽真空以及将反应产物从反应瓶中移出和移入，带有密封塞的反应瓶在高压下可操作。该模块化化学生产系统由模块组装而成，每个模块可以包括用于监测和控制各个模块和组装系统的操作条件传感器和控制器，可以从远程位置进行监控和控制。其他模块包括但不限于试剂储存和输送模块、柱层净化模块、微波反应模块、外部质控/分析/净化接口模块、等份取样模块、F-18 干燥模块、浓缩模块、辐射计数模块和毛细管反应器模块。
• Processes for the synthesis of chloroadenosine and methylthioadenosine
  申请人：——

  公开号：US20030181713A1

  公开（公告）日：2003-09-25

  An in situ process for preparing chloroadenosine is described, wherein adenosine in a non-aqueous solvent is reacted with a thionyl chloride and a pyridine to form a reaction solution; the non-aqueous solvent is exchanged with a lower alcohol, and a base is added to the reaction solution; and the resulting chloroadenosine is filtered, washed and dried. Additionally, a two-step process for the synthesis of methylthioadenosine using the chloroadenosine prepared in situ is described.

  本发明描述了一种制备氯腺苷的原位过程，其中在非水溶剂中反应腺苷、硫酰氯和吡啶以形成反应液；用低级醇取代非水溶剂，并向反应液中加入碱；然后过滤、洗涤和干燥得到氯腺苷。此外，还描述了一种使用原位制备的氯腺苷合成甲硫氨酸腺苷的两步法过程。
• Nucleic acid probes and methods
  申请人：Duke University

  公开号：US20020177695A1

  公开（公告）日：2002-11-28

  The present invention provides metal-containing purines, pyrimidines, nucleosides, nucleotides and oligonucleotides; including phosphoramidite and photolabile derivatives thereof, including methods of making and method of using same. The present invention provides a method for detection of nucleic acid sequences via electrochemical or photochemical means.

  本发明提供了含金属的嘌呤、嘧啶、核苷、核苷酸和寡核苷酸，包括其磷酰胺酰基和光致裂解衍生物，以及制备和使用它们的方法。本发明还提供了一种通过电化学或光化学手段检测核酸序列的方法。
• Combination therapies for treating methylthioadenosine phosphorylase deficient cells
  申请人：——

  公开号：US20040043959A1

  公开（公告）日：2004-03-04

  The present invention is directed to combination therapies for treating cell proliferative disorders associated with methylthioadenosine phosphorylase (MTAP) deficient cells in a mammal. The combination therapies selectively kill MTAP-deficient cells by administering an inhibitor of de novo inosinate synthesis and administering an anti-toxicity agent, wherein the inhibitors of de novo inosinate synthesis are inhibitors of glycinamide ribonucleotide formyltransferase (“GARFT”) and/or aminoinidazolecarboximide ribonucleotide formyltransferase (“AICARFT”), and the anti-toxicity agent is an MTAP substrate (e.g. methylthioadenosine or “MTA”), a precursor of MTA, an analog of an MTA precursor or a prodrug of an MTAP substrate.

  本发明涉及用于治疗哺乳动物中与甲基硫腺苷磷酸化酶（MTAP）缺乏细胞相关的细胞增殖性疾病的联合疗法。该联合疗法通过给予新生核苷酸合成抑制剂和给予抗毒性剂，选择性地杀死MTAP缺乏细胞，其中，新生核苷酸合成抑制剂是甘氨酰核苷酸甲酰转移酶（“GARFT”）和/或氨基咪唑羧酰核苷酸甲酰转移酶（“AICARFT”）的抑制剂，抗毒性剂是MTAP底物（例如，甲基硫腺苷或“MTA”），MTA的前体，MTA前体的类似物或MTAP底物的前药。